Neurological
Refine Search
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, are collaborating on a project to tackle the urgent and unmet needs of people living with mental health conditions. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Pharmaceutical
US pharma major AbbVie and Hungary’s Gedeon Richter have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. 1 November 2024
Biotechnology
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. 1 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biotechnology
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Biotechnology
US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. 30 October 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Pharmaceutical
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Biotechnology
Shares of Californian clinical-stage biotech Alto Neuroscience plummeted 70% to $4.36 yesterday, as is announced disappointing trial results for depression candidate. 24 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Biotechnology
A study by Australia’s Monash University has highlighted the benefit for pregnant women with multiple sclerosis (MS) who continue to take a disease-modifying treatment during and after pregnancy. 5 May 2021
Generics
London-listed Hikma Pharmaceuticals saw its share gain more than 2% to 2,415 pence by late morning, as the company, announces the approval of Kloxxado (naloxone hydrochloride) nasal spray 8mg, by the US Food and Drug Administration for the emergency treatment of known or suspected opioid overdose. 30 April 2021
Pharmaceutical
Rare forms of multiple sclerosis (MS) exhibit certain atypical imaging characteristics that are absent in typical MS, although the clinical features of these variants are similar to typical MS. 30 April 2021
Biotechnology
French neurodegenerative diseases specialist Pharnext has announced new results from an interim analysis of an ongoing open-label follow-up extension study (‘PLEO-CMT-FU trial’) following the first double-blind, placebo-controlled Phase III study (PLEO-CMT trial) of PXT3003 for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A). There is currently no approved drug treatment for CMT1A. 29 April 2021
Generics
Teva Pharmaceutical Industries yesterday reported results for the first quarter of 2021 that met earnings expectations but not sales, leading the Israeli generics giant’s shares nearly 2% lower at 3,271 shekels by close of trading on Wednesday. 29 April 2021
Pharmaceutical
Shares of French pharma major Sanofi edged up 1.7% to 86.84 euros, after the company posted first-quarter 2021 financial results that were hit by currency aspects. 28 April 2021
Biotechnology
The European Medicines Agency’s Committee for Medicinal Products for Human US (CHMP) recommended eight medicines for approval at its April 2021 meeting, five of which were novel drugs. 23 April 2021
Pharmaceutical
Ireland-headquartered Jazz Pharmaceuticals has announced positive results from a Phase III study of Xywav (calcium, magnesium, potassium, and sodium oxybates). 22 April 2021
Biotechnology
US biotech major Biogen today reported first quarter 2021 financial results which, though well below 2020 comparisons, beat analysts’ expectations. 22 April 2021
Biotechnology
Guernsey and Switzerland based Pureos Bioventure has announces the final closing of its first fund BB Pureos Bioventures LP with a committed capital of $205 million. 22 April 2021
Biotechnology
Japanese drugmaker Eisai, one of an increasingly small number of major players still working in the Alzheimer’s space, has published results from a Phase IIb trial of lecanemab. 20 April 2021
Biotechnology
US biotech major Biogen today announced new data from the Spinraza (nusinersen) clinical development program aimed at optimizing outcomes for people with spinal muscular atrophy (SMA) and advancing understanding of the disease. 19 April 2021
Biotechnology
Among last week’s notable news, Biogen and Sage Therapeutics presented new data on their essential tremor candidate SAGE-324, which raised questions on tolerability. Roche and Regeneron released Phase III data confirming the efficacy of their COVID-19 antibody cocktail – casirivimab and imdevimab – for the treatment of this infection. In another disappointment in the COVID-19 space, Merck & Co said it is discontinuing development of MK-7110 as a treatment for hospitalized patients. In the latest investigation of thromboembolic events linked to novel coronavirus vaccines, the US Food and Drug Administration has launched a review of Johnson & Johnson’s COVID-19 candidate. On the deal making front, the UK’s C4X Discovery signed an agreement with French pharma major Sanofi on an oral pre-clinical interleukin (IL)-17A inhibitor program. 18 April 2021
Biotechnology
Roche today announced new Ocrevus (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) as well as demonstrating high persistence and strong adherence to twice-yearly (six-monthly) dosing. 16 April 2021
Biotechnology
Cambridge, UK-based biotech Alchemab Therapeutics today announced the completion of a £60 million ($82 million) Series A financing round. 15 April 2021
Biotechnology
China’s SciNeuro Pharmaceuticals has entered into an exclusive license agreement with US pharma major Eli Lilly for the development and commercialization of alpha-synuclein targeted antibody therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan. 15 April 2021
Biotechnology
UK-based Actimed Therapeutics today announced it has licensed S-oxprenolol to US biotech Faraday Pharmaceuticals, which is focused on improving outcomes of critical illnesses. 13 April 2021
Biotechnology
Both companies in the CNS partnership of Sage Therapeutics (Nasdaq: SAGE) and Biogen (Nasdaq: BIIB) closed more than 2% lower on Monday. 13 April 2021
Pharmaceutical
Russian drugmaker Biocad says it has completed one of the stages of development of its new drug, which is designed for the treatment of spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 13 April 2021
Biotechnology
AELIS FARMA, a privately-held French biotech specializing in the treatment of brain disorders, has announced a boost for the Improving Cognition in Down Syndrome (ICOD) project. 9 April 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze